Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 1999

Filing Date
Filed March 2, 2000
Period End
December 31, 1999
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 2, 2000. Cited figures are marked; the original filing is the authoritative source.

Important discrepancy: the filing supplied is not from Merck & Co. (MRK).

It is the 10-K for Schering-Plough Corporation (NYSE, Commission file 1-6571) for the fiscal year ended December 31, 1999. The analysis below covers Schering-Plough. Please confirm the intended filing before relying on it for Merck.

Schering-Plough reported a strong 1999. Net sales rose 14% to $9.18 billiona, driven by volume growth of 13%. Net income grew 20% to $2.11 billion, and diluted EPS rose 20% to $1.42.

Growth was led by the allergy and respiratory franchise (CLARITIN, NASONEX, VANCENASE), which reached $3.85 billionb in sales, and by the anti-infective and anticancer category (INTRON A and REBETRON for hepatitis C, plus TEMODAR), which grew 38% to $1.74 billion. Gross margin held near 80%, SG&A fell to 37.4% of sales from 38.9%, and R&D rose 18% to $1.19 billion (13.0% of sales). The effective tax rate was steady at 24.5%.

The key investor risks are concentration and litigation. CLARITIN's U.S. compound patent expires in 2002, and generic filers (Geneva, Teva, Copley, Novex, Zenith Goldline, and Andrx for CLARITIN-D) are challenging it.

The company also faces more than 110 antitrust actions, an ongoing FTC price-fixing investigation, a federal subpoena on disease management programs, an FDA Warning Letter on its New Jersey aerosol plants, and a Biogen royalty arbitration. Balance sheet strength is solid: cash of $1.88 billionc, debt at 12% of total capital, and operating cash flow of $1.89 billion, which covered $716 million in dividends and $504 million in buybacks.

Key Highlights

  1. Net sales of $9.18 billion in 1999, up 14% from $8.08 billion in 1998 (volume +13%, price +1%)
  2. Net income of $2.11 billion (+20%) and diluted EPS of $1.42 (+20%); effective tax rate of 24.5%
  3. CLARITIN franchise sales of $2.7 billion, with the allergy and respiratory category up 14% to $3.85 billion
  4. INTRON A and REBETRON hepatitis C combination sales of $1.1 billion, up 56%; TEMODAR launched in the U.S. and internationally
  5. R&D spending rose 18% to $1.19 billion (13% of sales), with 2000 R&D guided up about 15%
  6. Key risks: CLARITIN U.S. compound patent expires in 2002 and is under generic challenge; more than 110 antitrust suits; open FTC investigation; FDA Warning Letter on New Jersey aerosol plants
  7. Strong cash position: $1.88 billion in cash, $1.2 billion in unused credit lines, AA/Aa2 ratings, and $1.89 billion operating cash flow funding $716 million in dividends and $504 million in buybacks

Frequently Asked Questions

  1. Is this filing from Merck & Co. (MRK)?

    No. The document is the 10-K of Schering-Plough Corporation (fiscal year 1999, Commission file 1-6571, Madison, New Jersey). The filing does not match the Merck identification given in the request, so it should be checked before it is used for Merck analysis.

  2. What drove Schering-Plough's 1999 growth?

    Growth came mainly from the CLARITIN allergy franchise, which reached $2.7 billion in worldwide sales, and from the INTRON A and REBETRON hepatitis C products, which grew 56% to $1.1 billion. Foreign exchange had a minimal effect, reducing sales growth by less than 1%.

  3. What is the biggest long-term risk to revenue?

    The main risk is patent expiry for CLARITIN. The U.S. loratadine compound patent expires in 2002, and the desloratadine patent expires in 2004. Several generic filers are challenging these patents in court. Management says the company should prevail but cannot guarantee it. The filing also flags that major products such as CLARITIN and INTRON A/REBETRON account for a material share of revenue.

  4. What legal and regulatory exposures could affect results?

    Exposures include an FTC investigation into alleged drug price-fixing, a federal subpoena on disease management and rebate practices, more than 110 antitrust actions by pharmacies and consumers, a diethylstilbestrol (synthetic estrogen) suit involving about 400 plaintiffs claiming more than $1.5 billion, an FDA Warning Letter on aerosol products (albuterol and VANCERIL), and a Biogen royalty arbitration. Management considers material liability beyond amounts accrued to be remote in several of these matters, but the outcomes cannot be predicted.

  5. How strong is the company's financial position and capital return?

    Schering-Plough ended 1999 with $1.88 billion in cash, shareholders' equity of $5.17 billion, and a debt-to-total-capital ratio of 12%. Operating cash flow was $1.89 billion, which covered capital expenditures of $543 million, dividends of $716 million (up from $0.425 to $0.485 per share), and share repurchases of $504 million. The company holds $1.2 billion in unused credit lines and carries AA and Aa2 bond ratings.